Can High Phosphorus Cause Itching and How to Manage It?

High phosphorus levels are closely tied to itching in people with chronic kidney disease, but the connection is less straightforward than “phosphorus goes up, itching starts.” The itch associated with kidney disease, often called uremic pruritus, involves a tangle of metabolic disruptions that phosphorus participates in rather than single-handedly causes. Lowering phosphorus alone does not reliably stop the itch, and some large analyses have found surprisingly little direct correlation between phosphate levels and itch severity at any given moment. That disconnect matters, because it shapes how you and your care team should approach the problem.

How Phosphorus Gets Tangled Up With Itching

When your kidneys lose the ability to excrete phosphorus efficiently, blood levels rise. That rise triggers a cascade of mineral imbalances: calcium drops, active vitamin D production falls, and parathyroid hormone climbs in an attempt to compensate. These shifts are extremely common in dialysis patients. Research shows that nearly all hemodialysis patients have insufficient vitamin D levels, and the majority have levels low enough to be classified as outright deficient.¹

The itching piece enters through the skin itself. Calcium normally exists in a gradient across the layers of the epidermis, and that gradient is essential for healthy skin barrier function. In hemodialysis patients who itch, the calcium distribution across their skin layers is disrupted: the deepest layer accumulates too much calcium while the middle layers show an abnormally flat, uniform distribution. This disturbance impairs the way skin cells mature and compromises the barrier formed by the outermost layer, the stratum corneum. Damaged skin barriers let irritants in and moisture out, and the resulting dryness and inflammation feed into itching.¹

So phosphorus does not irritate the skin directly. Instead, it drives the mineral and hormonal imbalances that disrupt calcium handling in the skin, degrade the skin barrier, and prime the body for chronic itch. Other factors pile on too: retained uremic toxins, sweat gland atrophy causing dry skin, immune system dysregulation, and even opioid receptor imbalances in the nervous system all play roles.² This multi-layered cause is why treating the itch requires more than phosphorus control alone.

Why Lowering Phosphorus Does Not Always Stop the Itch

If phosphorus were the main driver of itch intensity, you would expect a tight relationship between someone’s serum phosphate number and how badly they itch. A large post hoc analysis looked at exactly this question using data from clinical trials of difelikefalin, a drug tested in hemodialysis patients with moderate-to-severe itching. The researchers checked whether baseline phosphate predicted itch severity, whether phosphate at week 12 predicted itch severity, and whether changes in phosphate tracked with changes in itch scores. Across every comparison, the correlation was essentially zero.³

That finding does not mean phosphorus is irrelevant. It means that by the time someone has developed severe uremic itch, their phosphate level on a given day is a poor predictor of how bad the itching feels. The damage to the skin barrier, the accumulated mineral dysregulation, and the neurological sensitization have already set in. Bringing phosphorus into range is still worthwhile for cardiovascular health, bone health, and slowing disease progression, but expecting a quick itch fix from a lower phosphate number alone would be setting yourself up for disappointment.

Who Gets Hit Hardest

Uremic pruritus is widespread among dialysis patients, though severity varies enormously. A cross-sectional study of chronic hemodialysis patients found that about one in ten experienced severe itching, with the average itch score sitting at a moderate level.⁴ But the people in that severe category pay a steep price. Patients with uremic pruritus score significantly worse on quality-of-life measures, and sleep quality deteriorates as itch severity climbs.⁵

Older dialysis patients face a particularly rough combination. Research in geriatric hemodialysis patients found that those with uremic pruritus had higher rates of depressive symptoms, worse cognitive function, greater dependence in daily activities, and more disturbed sleep compared with patients who did not itch. Itch severity tracked positively with age, depression scores, and sleep disturbance, and negatively with how long patients had been on dialysis and their cognitive test scores.⁶ The itch becomes part of a vicious cycle: poor sleep worsens depression, depression amplifies the perception of itch, and the combination erodes functional independence.

Managing Phosphorus Through Diet

Dietary phosphorus restriction is one of the first tools your kidney care team will recommend, but it is trickier than it sounds. The challenge is that phosphorus is everywhere in the modern food supply, and not all phosphorus is absorbed equally. Your gut absorbs roughly 40 to 60 percent of the phosphorus naturally present in animal-based foods like meat and dairy.⁷ Plant-based phosphorus, which is largely bound up in a compound called phytate, is absorbed at lower rates, often under 40 percent.⁸

The real problem is inorganic phosphorus added to processed foods as preservatives, emulsifiers, and flavor enhancers. This form can be absorbed at rates approaching 100 percent.⁷ Processed cheese, deli meats, fast food, and many soft drinks (particularly colas) are loaded with these additives. The practical difference is enormous: you could eat a piece of grilled chicken and absorb a moderate fraction of its phosphorus, or eat a processed chicken nugget with phosphate additives and absorb nearly all of it.

Making this harder, food labels provide very little information about phosphorus content. A study examining processed foods found that product labels often failed to disclose phosphorus amounts, and measured phosphorus content sometimes differed substantially from what food composition tables listed.⁹ The most practical advice is to scan ingredient lists for terms containing “phos” (sodium phosphate, phosphoric acid, calcium phosphate, and so on) and limit processed foods as much as you can. Choosing whole foods over processed versions of the same product generally cuts phosphorus intake without sacrificing protein, which matters because overly restrictive diets can lead to protein-energy wasting, itself a serious risk in kidney disease.¹⁰

Phosphate Binders and How They Work

When diet alone cannot control phosphorus, medications called phosphate binders are the standard next step. You take them with meals, and they bind to phosphorus in the food you eat before your gut can absorb it. The bound phosphorus then passes out in your stool. There are two broad categories: calcium-based binders and non-calcium-based binders, and the choice between them involves real trade-offs.

Among calcium-based options, calcium acetate lowers serum phosphorus more effectively than calcium carbonate. A meta-analysis of trials comparing the two found that calcium acetate produced significantly lower phosphorus levels after both four and eight weeks of treatment, without increasing the risk of high calcium levels. The trade-off was tolerability: patients on calcium acetate were roughly three and a half times more likely to experience side effects severe enough to be categorized as intolerance.¹¹ Gastrointestinal complaints, especially nausea, are the usual issue.

Non-calcium binders like sevelamer and lanthanum carbonate avoid the calcium load entirely, which is appealing because excess calcium can contribute to vascular calcification over time. Both drugs bring phosphorus down effectively. In a comparative study of CKD patients in stages III and IV, sevelamer carbonate reduced average serum phosphate from about 8.3 to 5.1 mg/dL over six months, while lanthanum carbonate reduced it from about 8.8 to 4.0 mg/dL.¹² Beyond phosphorus, non-calcium binders appear to lower FGF-23, a hormone that rises in kidney disease and drives harmful cardiovascular effects, more than calcium-based binders do.¹³

Pill burden is a real-world barrier. Sevelamer in particular requires multiple large tablets with every meal, which can feel overwhelming on top of an already complicated medication list. Switching to lanthanum carbonate can reduce the number of daily pills without losing phosphorus control, and may save on drug costs as well.¹⁴

A newer option, tenapanor, works by a completely different mechanism. Instead of binding phosphorus in the gut, it inhibits a sodium transporter in the intestinal lining. This raises the pH inside the gut in a way that reduces the amount of phosphorus that can pass through the intestinal wall, effectively blocking absorption at the tissue level rather than chemically trapping the mineral.¹⁵ Tenapanor was originally developed for irritable bowel syndrome, and its low pill burden makes it an attractive add-on or alternative for people who struggle with traditional binders.

What Dialysis Can and Cannot Do for Phosphorus

A single hemodialysis session does pull phosphorus out of the blood. On average, patients see a drop of about 2.85 mg/dL immediately after a session. But that number bounces back quickly. Within 24 hours, most patients had not returned to their pre-dialysis level, but by 48 hours, serum phosphate had climbed back to about 94 percent of where it started.¹⁶ Phosphorus stored in bone and soft tissues slowly re-enters the bloodstream between sessions, which is why dialysis alone, even when done well, cannot keep phosphorus consistently low without dietary control and binders.

The dialyzer itself matters. Larger dialyzer surface area and higher ultrafiltration rates improve phosphorus removal during a session.¹⁷ More frequent or longer dialysis sessions, such as nocturnal or daily short sessions, can improve phosphorus clearance over a week compared to the standard three-times-a-week schedule, though access to these schedules varies by center and insurance coverage.

Treating the Itch Directly

Because phosphorus control alone does not reliably resolve the itch, targeted therapies are often necessary. The approach typically starts simple and escalates based on how you respond.

Emollients, topical analgesics like capsaicin or pramoxine, oral antihistamines, and gabapentin are the first-line options most patients try.¹⁸ Moisturizers address the dry, compromised skin barrier directly, and they are worth maintaining even if they do not fully control the itch. Gabapentin can help because it dampens the nerve signaling that drives the itch sensation, though it requires dose adjustment for kidney function.

For patients who do not get enough relief from those options, difelikefalin represents a genuine advance. This drug works on kappa-opioid receptors in the peripheral nervous system, which are involved in suppressing itch signals. In a phase 3 trial of hemodialysis patients with moderate-to-severe pruritus, about half of the patients receiving difelikefalin achieved a meaningful reduction in itch scores, compared with roughly a third on placebo.¹⁹ A pooled analysis of two large trials confirmed these results and showed that improvements started within the first week of treatment and were sustained for over a year.²⁰ Difelikefalin is given intravenously at the end of a dialysis session, which removes the burden of taking another pill at home.

Another opioid-based therapy, nalfurafine, has shown symptom relief in multiple studies and carries a low risk of the kind of euphoria or dependence associated with traditional opioids.²¹ It is approved in Japan but not widely available in many other countries, so access depends on where you live.

Narrowband UVB Phototherapy

For patients whose itch resists medication, narrowband ultraviolet B (NB-UVB) phototherapy is a well-supported option. This treatment involves standing in a specialized light booth two or three times a week. The UV light reduces skin inflammation, modulates the local immune response, and may alter nerve fiber density in the skin.

A prospective study of hemodialysis patients found that itch scores dropped significantly from baseline after eight weeks of treatment, with over half of patients achieving a 50 percent or greater reduction in itch intensity. The improvement was dose-dependent, meaning higher cumulative UVB doses produced better results, and no harmful effects on kidney function were observed.²² Improvement often begins around the sixth session, with most patients needing about 13 sessions on average to reach full benefit.²³

An interesting wrinkle: vitamin D levels appear to influence how well phototherapy works. Patients whose vitamin D levels rose more during treatment responded faster. A study found that the magnitude of vitamin D increase was independently associated with being a rapid responder to UVB therapy.¹⁸ Since UVB light stimulates vitamin D production in the skin, and since kidney disease causes vitamin D deficiency that contributes to the mineral imbalances discussed earlier, phototherapy may partially work by correcting a piece of the metabolic puzzle rather than only by quieting local inflammation.

Acute Phosphorus Spikes in Unexpected Places

Most discussions of high phosphorus and itching focus on the chronic situation of kidney disease, but acute spikes deserve a mention because they catch people off guard. Oral sodium phosphate-based laxatives, commonly used for bowel preparation before colonoscopy or for constipation relief, cause measurable increases in serum phosphorus in nearly everyone who takes them. In healthy people these spikes are small and temporary, but in older adults, people with any degree of kidney impairment, or people with slow gut motility, the spike can be severe. Severe hyperphosphatemia paired with a sudden calcium drop can become a medical emergency.²⁴

If you have kidney disease and are scheduled for a procedure requiring bowel prep, make sure your team knows your kidney status. Alternative prep solutions that do not contain phosphorus are widely available. The same caution applies to over-the-counter phosphate-based laxatives and enemas: they are not as benign as the label might suggest when your kidneys cannot clear the extra phosphorus load efficiently.

Reading Food Labels When Phosphorus Is Not Listed

Phosphorus labeling is a genuine gap in consumer food information. Unlike sodium, sugar, or saturated fat, phosphorus is not required on the Nutrition Facts panel in most countries. You can eat a product loaded with phosphate additives and have no way to know the actual milligram amount from the label. Researchers have documented this disconnect directly, finding that phosphorus levels measured in processed foods often did not match published food composition tables, and that labels provided little useful information about phosphorus content.⁹

Until labeling regulations catch up, the ingredient list is your best tool. Look for any of these common additive names:

Sodium phosphate: used as a preservative and texture modifier in deli meats and canned soups
Phosphoric acid: gives cola beverages their tangy bite
Calcium phosphate: used as a leavening agent in baked goods and as a supplement filler
Sodium tripolyphosphate: common in frozen seafood to retain water weight

The strategy that dietitians who specialize in kidney disease generally recommend is to keep protein intake adequate (since restricting it too aggressively causes its own serious problems) while shifting the source of that protein toward less-processed options with lower phosphorus bioavailability. Choosing whole cuts of meat over processed versions, beans over deli meats, and cooking from scratch where feasible all reduce the hidden phosphorus load without compromising nutrition.¹⁰